<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-30T00:06:19Z</responseDate><request verb="GetRecord" identifier="oai:munzur-rdlopen.rawdatalibrary.net:munzur/4372" metadataPrefix="oai_dc">https://munzur-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:munzur-rdlopen.rawdatalibrary.net:munzur/4372</identifier><datestamp>2026-10-28T15:47:44Z</datestamp><setSpec>openaire</setSpec><setSpec>com_munzur_1</setSpec><setSpec>col_munzur_2</setSpec><setSpec>com_munzur_8</setSpec><setSpec>col_munzur_154</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Anticancer and Cytotoxic Activities of [Cu(C6H16N2O2)2][Ni(CN)4] and [Cu(C6H16N2O2) Pd(CN)4] Cyanidometallate Compounds on HT29, HeLa, C6 and Vero Cell Lines</dc:title><dc:creator>Aydin, Ali</dc:creator><dc:creator>Korkmaz, Sengul Aslan</dc:creator><dc:creator>Demir, Veysel</dc:creator><dc:creator>Tekin, Saban</dc:creator><dc:subject>Cyanidometallate compound</dc:subject><dc:subject>palladium</dc:subject><dc:subject>copper</dc:subject><dc:subject>nickel</dc:subject><dc:subject>antiproliferative effect</dc:subject><dc:subject>apoptosis</dc:subject><dc:description>Background: In cancer, apoptosis relevant proteins-such as CaM kinase, Bcl-2 or P53, topoisomerase I, cell migration feature and DNA/BSA-macromolecules represent significant targets for current chemotherapeutics. Objective: We recently reported two coordination compounds-[Cu(C6H16N2O2)(2)][Ni(CN)(4)] (1) and [Cu(C6H16 N2O2) Pd(CN)(4)] (2)-together with their IR spectra, magnetic properties, thermal analyses and crystal structures. Herein, we describe the ability of these complexes to induce apoptosis in relevant proteins and stimulate topoisomerase I activity, cell migration velocity and DNA/BSA binding properties. Method: The in vitro antiproliferative effects and cell toxicity of both compounds were investigated through pharmacological measurement techniques, and interactions between both compounds and CT-DNA/BSA were studied with UV-Vis spectroscopy and fluorescence spectroscopy. Results &amp; Conclusion: Studies on cells revealed that 2 (i) demonstrated a high antiproliferative effect, which was higher toward HeLa and C6 cancer cells than toward healthy Vero cells; (ii) impaired the migration of HeLa cells; (iii) altered the P53-Bcl-2 ratio in favor of apoptosis; (iv) strongly bound to DNA/BSA macromolecules; and (v) inhibited human topoisomerase I and KpnI or BamHI restriction endonucleases. In conclusion, this preliminary information demonstrates that 2 may represent a promising antiproliferative agent and a potential candidate for a therapeutic approach against HeLa.</dc:description><dc:publisher>BENTHAM SCIENCE PUBL LTD</dc:publisher><dc:date>2017</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/munzur/4372</dc:identifier><dc:identifier>https://doi.org/10.2174/1871520617666170103102417</dc:identifier><dc:identifier>1871-5206</dc:identifier><dc:language>en</dc:language><dc:relation>ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY</dc:relation><dc:rights>info:eu-repo/semantics/closedAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://munzur-rdlopen.rawdatalibrary.net/tr/items/munzur/4372</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>